Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia
Authors:
- Athithan RattanaburiARAthithan Rattanaburi
- Sathana BoonyapipatSBSathana Boonyapipat
- Yuthasak SupasinthYSYuthasak Supasinth
Open Access
- 13 July 2015
- journal article
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 16 (12) , 5037-5041
Abstract
An hCG regression curve has been used to predict the natural history and response to chemotherapy in gestational trophoblastic disease. We constructed hCG regression curves in high-risk gestational trophoblastic neoplasia (GTN) treated with EMA/CO and identified an optimal hCG level to detect EMA/CO resistance in GTN. Eighty-one women with GTN treated with EMA/CO were classified as primary high-risk GTN (n=65) and single agent-resistance GTN (n=16). The hCG levels prior to each course of chemotherapy were plotted in the 10th, 50th, and 90th percentiles to construct the hCG regression curves. Diagnostic performance was evaluated for an optimal cut-off value. The median hCG levels were 264,482 mIU/mL mIU/mL and 495.5 mIU/mL mIU/mL for primary high-risk GTN and single agent-resistance GTN, respectively. The 50th percentile of the hCG level in primary high-risk GTN and single agent-resistance turned to normal before the 4th and the 2nd course of chemotherapy, respectively. The 90th percentile of the hCG level in primary high-risk GTN and single agent-resistance turned to normal before the 9th and the 2nd course of chemotherapy, respectively. The hCG level of ≥118.6 mIU/mL mIU/mL at the 5thcourse of EMA/CO predicted the EMA/CO resistance in primary high-risk GTN patients with a sensitivity of 85.7% and a specificity of 100%. EMA/CO resistance in primary high-risk GTN can be predicted by using an hCG regression curve in combination with the cut-off value of 118.6 mIU/mL at the 5thcourse of chemotherapy.Keywords
This publication has 16 references indexed in Scilit:
- Evaluation of a novel training package among frontline maternal, newborn, and child health workers in South SudanInternational Journal of Gynecology & Obstetrics, 2012
- Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapyAnnals of Oncology, 2012
- Resistant Gestational Trophoblastic Neoplasia Patients Treated with 5-Fluouracil plus Actinomycin DAsian Pacific Journal of Cancer Prevention, 2012
- Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasiaAmerican Journal of Obstetrics and Gynecology, 2011
- Successful salvage of a relapsed high risk gestational trophoblastic neoplasia patient using capecitabineGynecologic Oncology, 2007
- Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy☆Gynecologic Oncology, 2003
- Gestational trophoblastic neoplasia, FIGO 2000 staging and classificationInternational Journal of Gynecology & Obstetrics, 2003
- EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients.Journal of Clinical Oncology, 1997
- Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989BJOG: An International Journal of Obstetrics & Gynaecology, 1991
- EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT)Gynecologic Oncology, 1988